Treatment of Recurrent VA in Patients With NICM e310 7.3. Arrhythmogenic Right Ventricular Cardiomyopathy e312 7.4. Hypertrophic Cardiomyopathy e315 7.5. Myocarditis e318 7.6. Cardiac Sarcoidosis e318 7.6.1. Other Infiltrative Cardiomyopathies e320 7.7. Heart Failure e321 7.7.1. HF With Reduced Ejection Fraction e321 7.7.2. HF With Preserved Ejection Fraction e321 7.7.3. Left Ventricular Assist Device e322 7.7.4. ICD Use After Heart Transplantation e322 7.8. Neuromuscular Disorders e322 7.9. Cardiac Channelopathies e324 7.9.1. Specific Cardiac Channelopathy Syndromes e325 8. VA in the Structurally Normal Heart e334 8.1. Outflow Tract and Atrioventricular Annular VA e335 8.2. Papillary Muscle VA e335 8.3. Interfascicular Reentrant VT (Belhassen Tachycardia) e335 8.4. Idiopathic Polymorphic VT/VF e336 9. PVC-Induced Cardiomyopathy e337 10. VA and SCD Related to Specific Populations e338 10.1. Athletes e338 10.2. Pregnancy e338 10.3. Older Patients With Comorbidities e339 10.4. Chronic Kidney Disease e340 10.5. Valvular Heart Disease e340 10.6. Sex-Related Differences in the Risk of SCD e340 10.7. Medication-Induced Arrhythmias e341 10.8. Adult Congenital Heart Disease e342 11. Defibrillators Other than Transvenous ICDs e347 11.1. Subcutaneous Implantable Cardioverter-Defibrillator e347 11.2. Wearable Cardioverter-Defibrillator e348 11.3. Automated External Defibrillator e349 12. Special Considerations for Catheter Ablation e349 13. Postmortem Evaluation of SCD e350 14. Terminal Care e351 15. Shared Decision-Making e351 CLINICAL STATEMENTS AND GUIDELINES 16. Cost and Value Considerations e352 17. Quality of Life e353 18. Evidence Gaps and Future Research Needs e354 Appendix 1: Author Relationships With Industry and Other Entities (Relevant) e387 Appendix 2: Reviewer Relationships With Industry and Other Entities (Comprehensive) e389 PREAMBLE Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic meth- ods to evaluate and classify evidence, provide a corner- stone for quality cardiovascular care. 